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Pharmacological resistance is a serious threat to the
clinical success of hormone therapy for breast cancer. The
antiproliferative response to antagonistic drugs such as
tamoxifen (Tam) critically depends on the recruitment of
NCoR/SMRT corepressors to estrogen receptor alpha
(ERa) bound to estrogen target genes. Under certain
circumstances, as demonstrated in the case of interleukin-
1b (IL-1b) treatment, the protein Tab2 interacts with
ERa/NCoR and causes dismissal of NCoR from these
genes, leading to loss of the antiproliferative response. In
Tam-resistant (TamR) ER-positive breast cancer cells, we
observed that Tab2 presents a shift in mobility on sodium
dodecyl sulfate–PAGE (SDS-PAGE) similar to that seen
in MCF7 wt upon stimulation with IL-1b, suggesting
constitutive activation. Accordingly, TamR treatment
with Tab2-specific short interfering RNA, restored the
antiproliferative response to Tam in these cells. As
Tab2 is known to directly interact with the
N-terminal domain of ERa, we synthesized a peptide
composed of a 14-aa motif of this domain, which
effectively competes with ERa/Tab2 interaction in pull-
down and co-immunoprecipitation experiments, fused to
the carrier TAT peptide to allow internalization. Treat-
ment of TamR cells with this peptide resulted in partial
recovery of the antiproliferative response to Tam,
suggesting a strategy to revert pharmacological resistance
in breast cancer. Silencing of Tab2 in TamR cells by
siRNA caused modulation of a gene set related to the
control of cell cycle and extensively connected to BRCA1
in a functional network. These genes were able to discern
two groups of patients, from a published data set of
Tam-treated breast cancer profiles, with significantly
different disease-free survival. Altogether, our data
implicate Tab2 as a mediator of resistance to endocrine
therapy and as a potential new target to reverse
pharmacological resistance and potentiate antiestrogen
action.
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Introduction
Tamoxifen (Tam) is by far the most widely used drug for
hormone-dependent breast cancer and the use of this or
similar drugs since 1980 has led to reduction in
the annual breast cancer death rate by nearly a third
(ECBCT, 2005) and contributed significantly to
improvement in long-term survival. However, primary
or acquired resistance to Tam severely limits its clinical
effectiveness (Hughes-Davies et al., 2009). Recently,
another class of antiestrogenic drugs was introduced,
namely the so-called third-generation aromatase inhibi-
tors, showing very good efficacy (ECBCT, 2005;
Dowsett et al., 2010). Significant advantage is obtained
by switching from initial Tam to AI, demonstrating that
late failure of Tam could be attributed, at least in part,
to acquired pharmacological resistance.
When estrogen receptor alpha (ERa) binds to Tam or
other selective ER modulators it undergoes activation,
dimerization and binding to cognate elements in DNA.
Tam-bound ERa displays increased affinity for core-
pressor proteins and decreased affinity for coactivators
(Shiau et al., 1998; Perissi and Rosenfeld, 2005), as
opposed to estrogen-bound ERa. As a result, estrogen-
dependent genes are actively repressed and cell growth
stops. In the breast, Tam-repressive effect is due, in part,
to interaction with NCoR and SMRT corepressors,
possibly showing a remarkable gene specificity (Keeton
and Brown, 2005). NCoR and SMRT make part of
large multiprotein complexes, where various compo-
nents are sensors for other perceptive or proprioceptive
signals coming to the genome (Perissi et al., 2010). These
components may alter the phosphorylation state, the
stability and the distribution of corepressors, changing
their activity to various degrees, up to the complete
reversal of gene repression. One of these proteins, Tab2,
was characterized as a mediator of both TGF-b and
inflammatory cytokines (Takaesu et al., 2000; Broglie
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et al., 2010), but was also found as a facultative
component of the NCoR complex (Baek et al. 2002).
Studying antiandrogen-resistant prostate cancer cells, it
was found that interleukin-1b (IL-1b) induces phos-
phorylation of Tab2 engaged in the nucleus with NCoR
complexes, unmasking Tab2 ability to translocate to the
cytoplasm together with NCoR, thus dismissing repres-
sion from androgen-responsive genes and functionally
converting antiandrogenic compounds to androgenic
(Zhu et al., 2006). Interestingly, deletion of Tab2
resulted in reversal of IL-1b effect, demonstrating that
Tab2 is not essential to transcriptional repression by the
androgen receptor (AR). A similar mechanism was
observed in MCF7 breast cancer cells in response to
Tam, and indeed a conserved short motif was found in
the N-terminal domain of steroid receptor proteins (AR,
PgR, ERa) responsible for direct interaction between
the receptor and Tab2. In fact, a peptide mimic of this
region reverts IL-1b-induced NCoR dismissal when
microinjected in prostate cancer cell nuclei (Zhu et al.,
2006). A second interaction was demonstrated between
Tab2 and the first RID of NCoR (Baek et al., 2002).
The balance of coactivator to corepressor available at
the gene level defines a threshold from activation to
repression and may represent a general feature of
hormone resistance. Among the mechanisms proposed
to explain primary and acquired Tam resistance in
breast cancer cells that maintain expression of ERa,
there are constitutive activation of components of
signaling pathways stemming from membrane growth
factor receptors, resulting in re-distribution of coactiva-
tors or corepressors (Privalsky, 2004; Frogne et al.,
2005; Schiff et al., 2005; Frankel et al., 2007; Yue et al.,
2007; Pancholi et al., 2008; Musgrove and Sutherland,
2009). In addition, it was shown that the coactivator
SRC3/AIB1, which is often amplified and overexpressed
in breast cancer, induced Tam resistance in vitro
(Osborne et al., 2003), in a similar way as it did a
decreased level of NCoR corepressor (Lavinsky et al.,
1998).
In order to understand the possible role of Tab2 in the
control of Tam response in breast cancer cells, we set
out to interfere with Tab2 action in MCF7 derivatives
that were rendered resistant to Tam by continuous drug
exposure. We present evidence that Tab2 has a general
role in Tam resistance that bypasses its role in
inflammatory response and describe a lead compound
to reverse Tam resistance in breast cancer cells.
Results
Tab2 is involved in Tam resistance
In order to study the role of Tab2 in Tam resistance, we
used cell lines obtained from MCF7 breast carcinoma
cells by continuous passage in the presence of sub-lethal
doses of Tam (Lykkesfeldt and Briand, 1986; Madsen
et al., 1997). These cells, indicated here as TAMR-4.1,
TAMR-4.2 and TAMR-8, are slightly different in terms
of cell morphology, gene expression and growth rate
(for details, see Materials and methods). They all
maintain expression levels of ERa and NCoR similar
to wild-type MCF7 cells (MCF7 wt), while showing
lower expression of SMRT corepressor protein (not
shown), suggesting a more strict dependence on NCoR.
We have studied Tab2 expression in these TamR
sublines in the nuclear and cytoplasmatic fractions, as
compared withMCF7 wt, by immunoblotting (Figure 1).
IL-1b-treated MCF7 wt cells, where Tab2 is fully phos-
phorylated through MEKK1 (Zhu et al., 2006), were
used for comparison. As shown in Figure 1, whereas in
untreated MCF7 wt cells the prevalent Tab2 form is the
Figure 1 (a) Immunoblotting analysis of Tab2 in TamR cells as compared with MCF7 wt responding to IL-1b treatment. TamR cells
were transfected with control or Tab2 siRNA and kept in 1% DC-FBS for 48 h. MCF7 wt cells were kept in 1% DC-FBS for 3 days
then treated with 10 ng/ml IL-1b for 10min. MCF7 wt and TamR cells were subjected to cellular fractionation and the Tab2 protein
analyzed by immunoblotting in the cytoplasmatic and nuclear fractions. (b) Tab2 downregulation restores tamoxifen response in
TamR cells. MCF7 wt and TamR cells were transfected with control or Tab2 siRNA and 48 h later treated with 108 M E2 (white bars)
or 108 M E2 plus 106 M 4OHT (black bars). After 24 h, the proliferation was measured by 2 h bromo-deoxyuridine incorporation. Data
are means±s.d. of replicate experiments (MCF7wt and TamR-4.2 N¼ 4; TamR-4.1 N¼ 3; TamR-8 N¼ 5). *Denotes Pp0.05
(Mann–Whitney U test). More details are given as Supplementary Figure S2.
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lower band (unphosphorylated), in untreated TamR
cells Tab2 migrates as a doublet band in both
subcellular fractions, and the upper band is often
prevalent. Tab2 can be phosphorylated through differ-
ent pathways involving MEKK1 and p38 at different
sites (Baek et al., 2002; Rush et al., 2005; Mendoza et al.,
2008; Shin et al., 2009) so that our result may indicate
that Tab2 is constitutively activated in TamR cells. To
further verify this possibility, we have performed
experiments using the MEKK1 inhibitor U0126 and
the p38 inhibitor SB203580 in TamR cells, obtaining
visible reduction of the upper band in all cases
(Supplementary Figure S1).
Based on these results, we next examined how Tab2
may influence the response to Tam. TamR cells were
then transfected with Tab2-specific double helix inter-
fering RNA (siRNA) and after 48 h, when Tab2 protein
levels were 60–80% reduced, as evaluated by immuno-
blotting (Figure 1a), cells were treated with 4-OH-
tamoxifen (4OHT) and the rate of proliferation mea-
sured. Downregulation of Tab2 led to a significant
recovery of the antiproliferative response to Tam, which
was maximal in TAMR-8 and less accentuated in
TAMR-4.1 and TAMR-4.2 sublines (Figure 1b and
Supplementary Figure S2). It should be noted that in
these experiments, we compared 4OHT plus estradiol
with estradiol alone and, in such conditions, 4OHT
shows a little antiproliferative response (5–25%). How-
ever, in all cases downregulation of Tab2 significantly
increased the inhibitory effect of Tam. Similar results
were obtained in the presence of 4OHT only, although
in general somewhat less evident (not shown). These
results demonstrate a role of Tab2 in the resistance
mechanisms in these cells.
An ERa mimic peptide restores Tam response
As seen above, Tab2 is not required to obtain
antiproliferative response to Tam, suggesting that
functional NCoR corepressor complexes exist devoid
of Tab2, as also observed in different contexts (Baek
et al., 2002). Therefore, we reasoned that ERa/Tab2
could be the interaction responsible of recruiting Tab2
to corepressor complexes, causing Tab2 binding to
NCoR through interaction with the RID1 domain (Zhu
et al., 2006) and, if phosphorylated, eliciting NCoR
dismissal and export. Consequently, we hypothesized
that interfering with ERa/Tab2 interaction in TamR
cells would restore Tam response.
ERa/Tab2 interaction was investigated in more detail.
First, Flag-ERa efficiently coimmunoprecipitated Tab2,
and vice-versa (Figure 2a) when overexpressed in
HEK293T cells. Second, fragments of Tab2 of different
length were expressed in bacteria as MBP fusion
proteins. Both full length Tab2 and its central domain
(aa 406-531) were found to pull-down efficiently ERa
from lysates of overexpressing HEK293T cells
(Figure 2b). Taking advantage of the conservation
among sex steroid receptors, we selected a 14-aa region
of the hERa, corresponding to the androgen receptor
motif shown to be essential for AR/Tab2 interaction
(Zhu et al., 2006). A synthetic peptide corresponding to
this conserved sequence of human ERa, thereafter called
ERa-peptide, but not a mutated version (first 14 aa in
Figure 2c), was able to compete out efficiently the
in vitro biochemical Tab2/ERa interaction (Figure 2b).
Next, we addressed the question whether such an
interfering peptide could relieve Tab2 inhibition of Tam
response in cultured cells. In order to get internalization,
the 14-aa sequence used in in vitro experiments was
Figure 2 In vivo and in vitro interaction between Tab2 and ERa. (a) Coimmunoprecipitation of Tab2 and Flag-tagged ERa. Full
length Tab2 and Flag-tagged ERa were transiently overexpressed in HEK293T cells. Anti-Flag and anti-Tab2 immunoprecipitates
were carried out from nuclear extracts and were analyzed by immunoblotting with anti-Flag and anti-Tab2 antibodies. (b) Competition
of ERa peptide for Tab2/ERa interaction. MBP pull-down assays, using full length Tab2 or the Tab2 central domain (aa 406-531)
fused to MBP, and ERa overexpressed in HEK293T cells, in the presence of ERa-peptide or ERa mut-peptide. (c) Amino-acid
sequences of ERa-TAT peptide and mutated ERa-TAT peptide. The vertical bars indicate amino-acid changes.
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fused N-terminally to the minimized carrier sequence of
the viral TAT protein (Patel et al., 2007), to give the
23-aa sequence shown in Figure 2c, called ERa-TAT
peptide, and the corresponding mutated version. Cells
were then treated with 1 and 100 mM concentrations of
these peptides for 1 h in the absence of serum, then
serum was added back and the effect on cell prolifera-
tion was measured 24 h later. As shown in Figure 3a, the
ERa-TAT peptide, but not the mutated version, was
able to reduce the growth of TamR cells in the presence
of Tam. Cell treatment with 100 mM peptide produced a
21–84% growth inhibition when compared with cells
treated with the ERa mut-TAT control peptide. To
obtain proof of the action of ERa-peptide in vivo, we
overexpressed Flag-ERa and full length Tab2 in
HEK293T cells and treated them with 100 mM ERa-
TAT or ERa mut-TAT peptides for 3 or 6 h.
Co-immunoprecipitation analysis of nuclear extracts
showed that the ERa-peptide, but not the mutated
version, appreciably competed out the interaction
(Figure 3b). Altogether, these results suggest that
ERa/Tab2 interaction may take place in TamR cells,
and that interfering with this interaction can recover
Tam response in these cells. This observation may have
some importance for the development of pharmacolo-
gically useful compounds. To extend the generalization
of our observations, we examined the established breast
cancer cell line BT474, which shows amplification of the
ERBB2 gene, while maintaining ER expression, and
whose growth is not affected by Tam treatment. Also in
this case, the ERa-TAT peptide was able to recover the
antiproliferative response to Tam (23–44 vs 0–11% with
the mutated peptide) (Figure 3c), and similar results
were obtained by Tab2 downregulation using siRNA
(40–43 vs 12–15% with control siRNA) (Figure 3d),
suggesting a general role of Tab2 in the pharmacological
response to Tam in breast cancer cells.
Gene expression programs controlled by Tab2
In prostatic cancer cells treated with IL-1b, down-
regulation of Tab2 restored NCoR-mediated repression
of several genes in response to antiandrogenic com-
pounds (Zhu et al., 2006). Therefore, we examined gene
expression in TamR cells, under continuous Tam
treatment, after transfection of control or Tab2 siRNA.
Gene expression in TAMR-4.1, TAMR-4.2 and TAMR-8
was analyzed using a 44K feature microarray platform,
to ensure complete genomic coverage, by direct compar-
ison of control siRNA with Tab2 siRNA using the
double-color method and dye-swapping technical repli-
cate. We obtained a list of 282 probes concordantly
regulated in at least 2 out of 3 lines: of these, 51 were
significantly regulated in all 3 lines, and 239 showed
concordant regulation. The complete list of probes, with
the corresponding gene name, is given in Supplementary
Table S1. In order to get functional information from
this gene list, we carried out Gene Ontology and
pathway analysis using the Ingenuity platform. Table 1
shows top enriched molecular and cellular functional
categories that clearly point out to the main biological
Figure 3 An ERa mimic peptide restores tamoxifen response in
TamR cells. (a) TamR cells were treated with 1mM or 100mM ERa-
TAT peptide (black bars) or ERa mut-TAT peptide (white bars) in
absence of serum. After 1 h, 1% DC-FBS and 106 M 4OHT were
added for 24 h, then cell growth was measured as described in
Figure 1. Data are means±s.d. of triplicate experiments. (b) ERa-
TAT peptide competition on Tab2/ERa interaction in vivo. Full
length Tab2 and Flag-tagged ERa were transiently overexpressed
in HEK293T cells. The cells were treated with 100mM of ERa-TAT
or ERa mut-TAT peptides for 3 or 6 h in the presence of 4OHT.
Anti-Flag immunoprecipitates from nuclear extracts were analyzed
by immunoblotting with anti-Flag and anti-Tab2 antibodies. ‘m’
indicates untransfected HEK293T lysate. The ratio between anti-
Tab2 and anti-Flag for each treatment is indicated. (c) BT474 cells
were treated with ERa-TAT peptide (black bars) or ERa mut-TAT
peptide (white bars) and their growth was analyzed as above. Data
are from triplicate experiments. (d) BT474 cells were transfected
with control or Tab2 siRNA and then treated with 108 M E2 (white
bars) or 108 M E2 plus 106 M 4OHT (black bars). Data are
means±s.d. of duplicate experiments. *Denotes Pp0.05 as in
Figure 1.
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effect of Tab2 silencing in TamR cells, that is,
antiproliferative. Top network was ‘DNA Replication,
Recombination, and Repair, Cellular compromise, Cell
cycle’; top disease was ‘Cancer’; and top physiological
system was ‘Hair and skin development and function’
(Supplementary Table S2). Pathway analysis showed
that the described interaction network containing the
highest number of Tab2-regulated genes is centered
around the important breast cancer susceptibility gene
BRCA1 (Figure 4) that has important roles in transcrip-
tion, DNA repair of double-stranded breaks and
recombination. It is worth of note that, of the 35
proteins interconnected in this graph, 28 show some
degree of regulation by Tab2 siRNA treatment and,
most importantly, 21 of these are concordantly down-
regulated. The genes involved in the canonical BRCA1
pathway are shown in Supplementary Figure S3. We
also asked if the list of 282 Tab2-regulated genes contain
some known estrogen-regulated genes by comparing it
with the GEMS database (Ochsner et al., 2009). Using a
q-valueo0.05 for the choice, 49 common genes (Sup-
plementary Table S3) were found, comprising—among
the most known—CCNG2, DICER1 and IL1R1.
Finally, we reasoned that, if Tab2 has a general role in
Tam response in breast cancer, thus the expression
profile of the genes showing dependency on Tab2 in the
experimental setting should correlate with the relapse
rate in patients treated with adjuvant Tam. Hence, we
explored the data set published by Sotiriou et al. (2006)
that contains data on 64 ERþ patients, treated with
Tam in the adjuvant setting. A group of 212 probes,
among the 282 probes regulated by Tab2 siRNA in
TamR cells, selected on the basis of the ‘P’ value (see
Materials and methods) were able to discriminate very
significantly relapse-free survival of these patients
(Figure 5a), suggesting that their expression profile in
tumor cells may unravel a condition of relative
resistance to the treatment. As a very high number of
Tab2 siRNA-regulated genes belong to the BRCA1
network shown in Figure 4, we investigated whether this
group of genes was able to predict response. As shown
in Figure 5b, this subset (26 genes) was extremely
efficient in identifying relapsing patients; one branch
was completely free of events up to 7 years, whereas the
other felt down quickly, suggesting that this expression
profile marks hormone-resistant tumors.
Table 1 Molecular and cellular functions associated with Tab2
siRNA-regulated gene set (IPA, Ingenuity Systems)
Name P-value # Molecules
Cell Cycle 4.18E-06–4.63E-02 36
Cellular Assembly and
Organization
1.51E-04–3.93E-02 20
DNA Replication, Recombination,
and Repair
1.51E-04–3.93E-02 23
Cell Death 1.56E-04–3.41E-02 39
Cellular Development 5.22E-04–4.69E-02 29
Figure 4 Top network of Tab2 siRNA-regulated genes (IPA, Ingenuity Systems). Down (green) and up (red) regulated genes are
connected with continuous or dashed lines, indicating direct interactions experimentally proven and indirect connections, respectively.
Basc indicates the BRCA1 associated complex.
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Discussion
The data presented here demonstrate a role for Tab2 in the
pharmacological resistance to Tam, as its silencing by
siRNA leads to recovered inhibition of cell growth and
altered expression of cell cycle-related genes in Tam-
resistant breast cancer cells. In addition, we present evidence
that a peptide mimicking the Tab2-interacting domain of
ERa can represent a lead compound to reverse the
pharmacological resistance to Tam in breast cancer cells.
Tab2 is known as a player in the inflammatory signal
transduction pathway and was implicated in the reversal of
NCoR-dependent and NFkB- or APP-mediated gene
repression (Baek et al., 2002) and androgen antagonist
response in prostate cancer (Zhu et al., 2006). In addition, it
was identified as a cofactor for ERBB4 to assemble NCoR
corepressor complex in response to neuregulin (Sardi et al.,
2006). Although Tab2 was previously shown to mediate IL-
1b abrogation of Tam response in breast cancer cells (Zhu
et al., 2006), to our knowledge this is the first report
demonstrating that Tab2 is directly involved in the
acquisition of Tam resistance. In prostate cancer, a very
clear relationship between macrophage infiltration and
endocrine resistance was described (Zhu et al., 2006),
whereas in breast cancer this is less understood. However, it
may be of interest the fact that, looking for signatures
predictive of Tam response, Sotiriou and co-workers
identified a cluster of genes related to cellular inflammation,
further suggesting a link between these pathways (Loi et al.,
2008).
We did not directly evaluate differentially expressed
genes in our TamR cells in comparison to MCF7 wt, so
that we have no hint on which pathway(s) are activated
in these cells. Other TamR sublines derived in our
laboratories were shown to have constitutive activation
of Akt (Frogne et al., 2005) and increased level of PKCd
(Nabha et al., 2005) and PKCa (Frankel et al., 2007).
Other groups have reported that activation of several
growth factor receptor pathways, including ERBB2,
EGFR and PKA can lead to Tam resistance (Shou et al.,
2004; Yue et al., 2007; Pancholi et al., 2008). Interest-
ingly, we could demonstrate Tab2-dependency also in
BT474 cells, which carry amplified HER2. Together
with the observation that Tab2 migrated in SDS-PAA
gel electrophoresis as a phosphorylated form, these data
suggest that Tab2 may be constitutively activated by
unknown pathway(s) in TamR cells. Intriguingly, it has
been shown that EGFR may lead to Tab2 phosphoryla-
tion through p38/MAPK (Shin et al., 2009). In BT474
cells, downregulating Tab2 reduced the growth even in
the absence of Tam. It is conceivable that Tab2-driven
NCoR export is in part needed for the proliferative
response to the ERBB2-dependent pathway in these
cells. This effect was much less pronounced, yet present,
in our TamR sublines (Supplementary Figure S2).
Phosphorylation of Tab2 by MEKK1 following IL-1b
stimulation in prostate cancer cells led to delocalization of
NCoR to the cytoplasm (Baek et al., 2002; Zhu et al., 2006).
The same observation was reported by others in MCF7
cells in response to insulin (Carroll et al., 2003). We sought
to find evidence of NCoR delocalization in our TamR cells,
as well as reversal after Tab2 silencing by both immuno-
fluorescence and immunoblotting using cell fractionation.
Although some results could confirm this hypothesis, data
were not completely consistent, possibly due in part to the
fact that TamR and MCF7 wt grow optimally in very
different conditions, and do not allow robust conclusions,
so that we prefer not to present these data here.
Tab2 downregulation elicited some degree of growth
inhibition in all experimental conditions we tested, in both
TamR and MCF7 wt cells, suggesting that Tab2 may have
a role in cell growth that is not strictly dependent on its
function on Tam-regulated genes. However, the fact that an
ERa mimic peptide that competes with ERa/Tab2 interac-
tion in vitro and in vivo equally inhibits growth in the
presence of Tam strongly suggest that NCoR dismissal
from estrogen-regulated genes is, at least in part, the
mechanism operating in these cells.
The effect of Tab2 downregulation in TamR cells is
fully supported by microarray analysis results, showing
Figure 5 Association of Tab2 siRNA-regulated genes with survival in breast cancer patients treated with adjuvant tamoxifen
(Sotiriou et al., 2006). Regulation curves were calculated using the Kaplan–Meier statistics. (a) Sample clusters were obtained using 264
probes, corresponding to a subset of 212 Tab2 siRNA-regulated genes, selected on the combined P value (o0.05). (b) Sample clusters
were obtained using 43 probes, corresponding to 22 genes belonging to the network in Figure 4.
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that the mostly over-represented molecular and cellular
functions within the genes regulated by Tab2 siRNA
were related to cell cycle. Interestingly, the canonical
network with the highest enrichment score was centered
around BRCA1 that is the most important breast cancer
susceptibility gene and that is centrally involved in DNA
recombination and repair. The majority of genes in this
network were downregulated in response to Tab2
silencing, that is, when response to Tam is partially
restored. A negative effect of BRCA1 downregulation
on cell cycle is not straightforward, as it has been shown
that BRCA1 acts as a coactivator of p21(WAF1/CIP1)
(Lee et al., 2001). Nevertheless, this is consistent with the
fact that BRCA1 and most of the connected genes are
upregulated in response to estrogen, as we determined
exploring the GEMS database as well as our own data
(Cicatiello et al., 2004, 2010; Ochsner et al., 2009).
Furthermore, the association we have calculated be-
tween the expression of genes in BRCA1 network and
survival in breast cancer patients treated with Tam in
the adjuvant setting is impressive (Figure 5b). To our
knowledge, this is the first report linking these genes to
prediction of response to endocrine therapy. In general,
the subset of genes that are regulated following Tab2
silencing in TamR cells shows the same property, further
confirming that Tab2 may be critically linked to Tam
resistance in breast tumors.
In conclusion, we present here evidence that Tab2 is a
new player in pharmacological resistance to Tam in
breast cancer patients. Today, Tam is still first line
endocrine treatment for premenopausal women and,
even though selective ER modulators are more and
more replaced with third generation aromatase inhibi-
tors, there are suggestions that they still represent a valid
alternative (Hackshaw et al., 2011), especially if
predictive markers are identified to sort out patients to
the most appropriate endocrine treatment. Gene signa-
tures as those presented here may be further refined and
validated. Other groups have also presented interesting
results on Tam response prediction (Jansen et al., 2005;
Loi et al., 2008; Henriksen et al., 2009). Finally, we have
demonstrated that a cell permeable peptide, ERa-TAT,
that effectively competes out ERa/Tab2 interaction
in vivo, and restores in part Tam sensitivity in Tam-
resistant cells, is a promising peptide for further
pharmacological developments.
Materials and methods
Chemicals and antibodies
4-OHT and 17b-estradiol were purchased from Sigma-Aldrich
(St Louis, MO, USA). Human recombinant interleukin-1b was
from Calbiochem (San Diego, CA, USA). Polyclonal anti-ERa
antibody (H-184), anti-Tab2 (K-20), anti-Tab2 (H-300) and
anti-Tab2 (E-20) antibodies were from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). We used also a polyclonal
anti-Tab2 antibody from Bethyl Laboratories (Montgomery,
TX, USA) and a monoclonal anti-Hsp90 from Stressgene
Bioreagents Corp. (Victoria, BC, Canada). Monoclonal anti-
body anti-Flag was from Sigma-Aldrich. The ERa peptides
were synthesized and purchased from PolyPeptide Group SAS
(Strasbourg, France). The Tab2 (pool of three different Tab2
siRNAs) and untargeting control siRNAs were purchased
from Invitrogen (Life Technologies, Carlsbad, CA, USA).
Plasmids
The pCMV-T7 containing the full lenght hTab2 cDNA,
the hERa expression vector pHEGO, the p3XFLAG-CMV
containing the hERa cDNA were generous gifts from
Professor MG Rosenfeld (UCSD, La Jolla, CA, USA),
Professor P Chambon and Professor A Weisz (University of
Naples, Italy), respectively. The cDNA encoding human Tab2
full-length and the middle domain 406-531Tab2 were amplified
by PCR and cloned into pMALc2 vector. All constructs were
verified by automated DNA sequencing.
Cell lines and treatments
Tam-resistant cells were obtained by continuous passage of
MCF7 in the presence of sub-lethal doses of Tam (Lykkesfeldt
and Briand, 1986; Madsen et al., 1997). For the experiments,
we used two independent subcultures from MCF7/
TAMR-4 (independently passaged>15 times), here indicated
as TAMR-4.1 and TAMR-4.2, and the MCF7/TAMR-8 cell
line, indicated as TAMR-8. Resistant cells, collectively called
TamR, were continuously propagated in phenol red-free
Dulbecco’s modified Eagle’s medium (DMEM) /F12 1:1,
supplemented with 1% fetal bovine serum (FBS) and 106 M
4OHT. BT474 cell line was obtained from ATCC (HBT-20).
MCF7 wt and HEK293T cells were grown in high glucose
DMEM supplemented with 10% FBS. For Tab2 phosphor-
ylation, MCF7 wt cells were starved in 1% dextran/charcoal-
treated (DC) FBS for 3 days and then treated with 10 ng/ml
IL-1b in phenol red-free DMEM, 1% DC-FBS. For prolifera-
tion assays, MCF7 wt and TamR cells were maintained in
phenol red-free DMEM supplemented with 1% DC-FBS for
48 h, then 108 M E2±106 M 4OHT were added. Proliferation
was measured in quintuplicate by 2 h bromo-deoxyuridine
incorporation (Cell Proliferation Biotrak ELISA System kit,
GE-Healthcare, Bio-Sciences AB, Uppsala, Sweden) followed
by chemi-luminescence detection on a TECAN Infinite200.
Sub-cellular fractionation
Cells were lysed with 20mM Tris–HCl pH 8.0, 20mM NaCl,
0.5% NP-40, 1mM DTT, 1mM PMSF, 2mM Na3VO4, 50mM
NaF, 1X PIC for 10min and centrifuged at 12 000 g for 10 s.
The cytoplasmatic fraction was further cleared at 12 000 g
for 5min. The nuclear pellet was resuspended in 250mM
Sucrose, 10mM MgCl2, 1X PIC, layered on a cushion of
350mM Sucrose, 0.5mM MgCl2, 1X PIC and centrifuged at
8000 g for 10min. Nuclei were then resuspended in 20mM
Hepes pH 7.9, 25% glycerol, 420mM NaCl, 1.5mM MgCl2,
0.2mM EDTA, 1mM DTT, 0.1% NP-40, 1mM PMSF, 2mM
Na3VO4, 50mM NaF, 1X PIC, put on ice for 30min and
centrifuged at 12 000 g for 2min. The supernatant nuclear
extracts were diluted 1:3 in 20mM Hepes pH 8.
siRNA and gene Transfection
MCF7 wt, TamR and BT474 cells were plated at 6 103 cells/
well in 96-well plates, and after 18 h transfected with 20 nM
siRNAs. After 7 h, the medium was changed to phenol red-free
DMEM 1% DC-FBS, and 48 h after transfection cells were
treated for 24 h with 108 M E2±106 M 4OHT. HEK293T cells
were plated at 15 105 cells/plate in 100 20mm2 plates and
after 18 h transfected with 6 mg pCMV-T7-Tab2, 6mg
p3XFLAG-CMV-ERa or 6mg pHEGO using LipofectA-
MINE2000 (Invitrogen) according to the manufacturer’s
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instructions. After 4 h, the medium was changed to phenol red-
free DMEM 1% DC-FBSþ 106 M 4OHT for 48 h.
Treatment with peptides
1 mM and 100 mM of ERa-TAT or ERa mut-TAT peptides were
added to TamR, BT474 and HEK293T cells in phenol red-free
DMEMþ 106 M 4OHT in the absence of FBS, due to the low
stability of the peptide in serum. After 1 h, 1% DC-FBS was
added.
Coimmunoprecipitation, pull-down and immunoblotting
Coimmunoprecipitations of ERa and Tab2 were carried out
from nuclear extracts of HEK293T cells, using 1 mg of anti-
Flag antibody or a pool of 3mg of anti-Tab2 K-20, 3mg of
anti-Tab2 E-20 and 3mg of anti-Tab2 H-300 antibodies.
In vitro pull-down assays were done using MBP-Tab2 proteins,
ERa overexpressed in HEK293T cells, and synthetic ERa and
ERa mut peptides at a final concentration of 10mM.
Coimmunoprecipitation and pull-down assays were performed
using standard techniques as described in more details in the
Supplementary Methods. Specific bands were quantified by
densitometry, using the Quantity One 1-D Analysis Software
4.6.9 (Bio-Rad Laboratories Inc., Hercules, CA, USA).
Gene expression profiling and bioinformatic analysis
For microarray analysis, RNA quality, concentration and
labeling were checked by means of RNA 6000 nano chip
assays (Agilent Technologies, Palo Alto, CA, USA) and
NanoDrop ND-1000 Spectrophotometer (Thermo Scientific,
Waltham, MA, USA). Samples were checked for Tab2 mRNA
expression using real-time RT–PCR: reactions were carried
out according to the LightCycler Real-Time PCR System
(Roche Diagnostic, Indianapolis, IN, USA), using the SYBR
Green method and 18S RNA as normalizing target. Primers
for Tab2 and 18S were purchased from Qiagen, Hilden,
Germany. Each RNA sample pair (siTab2/siCtrl) was labeled
with Cy3 and Cy5 using the indirect method (Amino Allyl
MessageAmp II aRNA Kit, Ambion Inc., Grand Island, NY,
USA) and cohybridized to oligonucleotide glass arrays
representing 41K human unique genes and transcripts (Hu-
man Whole Genome Oligo Microarray Array 4x44K, Agilent
Technologies). Two replicates, with dye swap, were performed
for each sample. Slides were scanned with the dual-laser
microarray scanner Agilent G2505B (Agilent Technologies)
and data normalized and statistically evaluated using the
statistical computing software ‘R’. The Limma package
(Smyth et al., 2005) was used for preprocessing and differential
expression analysis. Further details on microarray analysis and
statistical calculations are available as Supplementary Meth-
ods. In order to find a group of genes regulated in the three
TamR cells examined, the following procedure was adopted.
Modulated gene lists for each subline were obtained using the
modified t-test supplied by the Limma package. Afterwards, a
final gene list was created by selecting genes with P-value less
than 0.1 in at least two of three TamR lines, to avoid bias due
to differences in sublines (Supplementary Table S1).
Gene ontology and molecular pathways analysis was
performed using Ingenuity Pathway Analysis software (version
9.0) (http://www.ingenuity.com). The analysis of publicly
available breast cancer data set was done by extracting
normalized values from (GSE2990) (Sotiriou et al., 2006),
containing data from 64 patients with primary breast tumors
treated with Tam in the adjuvant setting. Probes were
extracted from Tab2 downregulation experiments based on
the combined ‘P’ value in the three cell sublines examined.
Probes were referred to single entries in the NCBI genomic
database and mapped in the tumor microarray data set with no
assay to reduce multiple probes. Clustering was done using
TMEV (http://www.tm4.org/mev/) by Pearson or Spearman
correlation analysis and average linkage. The two major
branches of samples obtained were directly compared with
relapse-free survival or distant metastasis free-survival data, by
using the Kaplan–Meier statistics (PASW Statistics 18, SPSS,
Inc., 2009, Chicago, IL, USA, http://www.spss.com).
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